Cancer pharmacogenomics: international trends.
Cancer pharmacogenomics: international trends.
复制标题
DOI：
10.1007/s10147-004-0467-4
复制
发表时间：
2005-02-01
影响因子：
3.3
通讯作者：
Tanigawara, Yusuke
中科院分区：
文献类型：
--
作者：
Yamayoshi, Yasuko;Iida, Emiko;Tanigawara, Yusuke
众所周知，对许多药物的反应存在个体间的差异性。众所周知，许多非遗传因素，如年龄、性别、饮食和器官功能，都会影响药物的治疗效果。然而，药物基因组学的最新进展表明，基因多态也显著影响药物的疗效和毒性。编码药物代谢酶、转运蛋白和靶分子的基因突变可能会改变它们的表达、活性或对药物的亲和力，从而影响药物的药代动力学和药效学。许多研究报道了药物代谢酶、转运体、靶分子和DNA修复酶的多态性与治疗结果之间的相关性。这些药物基因组学的发现有望为癌症化疗的个体化和最优化提供帮助。
It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs' pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy.